Recombinant fragment corresponding to Human RIP aa 300-450 (internal sequence).
This product is a recombinant rabbit monoclonal antibody.
If you have any questions regarding this update, please contact our Scientific Support team.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Produced using Abcam's RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5, 675, 063 and/or 7, 429, 487.
We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.
Our Abpromise guarantee covers the use of ab125072 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/10000. Predicted molecular weight: 75 kDa.|
Lane 1: Wild-type HAP1 cell lysate (20 µg)
Lane 2: RIP knockout HAP1 cell lysate (20 µg)
Lane 3: HeLa cell lysate (20 µg)
Lane 4: Raji cell lysate (20 µg)
Lanes 1 - 4: Merged signal (red and green). Green - ab125072 observed at 78 kDa. Red - loading control, ab8245, observed at 37 kDa.
ab125072 was shown to specifically react with RIP when RIP knockout samples were used. Wild-type and RIP knockout samples were subjected to SDS-PAGE. ab125072 at a dilution of 1/1000 and ab8245 (loading control to GAPDH) at a dilution of 1/10,000 were incubated overnight at 4°C. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1/10,000 dilution for 1 hour at room temperature before imaging.
ab125072 has not yet been referenced specifically in any publications.